CN1646130A - 类风湿性关节炎的治疗 - Google Patents

类风湿性关节炎的治疗 Download PDF

Info

Publication number
CN1646130A
CN1646130A CNA038028808A CN03802880A CN1646130A CN 1646130 A CN1646130 A CN 1646130A CN A038028808 A CNA038028808 A CN A038028808A CN 03802880 A CN03802880 A CN 03802880A CN 1646130 A CN1646130 A CN 1646130A
Authority
CN
China
Prior art keywords
rheumatoid arthritis
treatment
methyl
formula
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038028808A
Other languages
English (en)
Chinese (zh)
Inventor
H·约恩苏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinki University Hospital
Original Assignee
Helsinki University Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinki University Hospital filed Critical Helsinki University Hospital
Publication of CN1646130A publication Critical patent/CN1646130A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA038028808A 2002-01-28 2003-01-27 类风湿性关节炎的治疗 Pending CN1646130A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0201882.8 2002-01-28
GBGB0201882.8A GB0201882D0 (en) 2002-01-28 2002-01-28 Organic compounds

Publications (1)

Publication Number Publication Date
CN1646130A true CN1646130A (zh) 2005-07-27

Family

ID=9929858

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038028808A Pending CN1646130A (zh) 2002-01-28 2003-01-27 类风湿性关节炎的治疗

Country Status (22)

Country Link
US (2) US20060264443A1 (enExample)
EP (1) EP1471916B1 (enExample)
JP (1) JP4398731B2 (enExample)
KR (1) KR101030416B1 (enExample)
CN (1) CN1646130A (enExample)
AT (1) ATE399555T1 (enExample)
BR (1) BR0307286A (enExample)
CA (1) CA2473158C (enExample)
DE (1) DE60321888D1 (enExample)
DK (1) DK1471916T3 (enExample)
ES (1) ES2309299T3 (enExample)
GB (1) GB0201882D0 (enExample)
IL (1) IL162983A (enExample)
MX (1) MXPA04007309A (enExample)
NO (1) NO328255B1 (enExample)
NZ (1) NZ534137A (enExample)
PL (1) PL212137B1 (enExample)
PT (1) PT1471916E (enExample)
RU (1) RU2322238C2 (enExample)
SI (1) SI1471916T1 (enExample)
WO (1) WO2003063844A2 (enExample)
ZA (1) ZA200405323B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102512421A (zh) * 2011-10-28 2012-06-27 中国科学院广州生物医药与健康研究院 哌嗪酰胺类化合物在制药中的新应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479257A1 (en) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
US20050130986A1 (en) * 2003-11-21 2005-06-16 Eklund Kari K. Treatment of spondylarthropathies
US20080248022A1 (en) * 2004-09-08 2008-10-09 Immunaid Pty Ltd Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
JP2010500283A (ja) * 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
RU2580656C1 (ru) * 2014-11-20 2016-04-10 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма гидроксихлорохина немедленного высвобождения и способ ее получения
US20210380685A1 (en) * 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316884A (en) * 1979-01-25 1982-02-23 Adria Laboratories, Inc. Sustained release pharmaceutical formulation
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW550258B (en) * 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1414500A4 (en) * 2001-04-16 2005-01-12 Uab Research Foundation Akt and regulation of ra synovial fibroblast apoptosis
AU2002342335B2 (en) * 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
ATE330608T1 (de) * 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102512421A (zh) * 2011-10-28 2012-06-27 中国科学院广州生物医药与健康研究院 哌嗪酰胺类化合物在制药中的新应用
CN102512421B (zh) * 2011-10-28 2013-11-06 中国科学院广州生物医药与健康研究院 哌嗪酰胺类化合物在制药中的应用

Also Published As

Publication number Publication date
ATE399555T1 (de) 2008-07-15
HK1072192A1 (en) 2005-08-19
EP1471916B1 (en) 2008-07-02
US20090131382A1 (en) 2009-05-21
NO20043585L (no) 2004-10-21
NO328255B1 (no) 2010-01-18
PL212137B1 (pl) 2012-08-31
PT1471916E (pt) 2008-10-03
WO2003063844A3 (en) 2004-04-01
ES2309299T3 (es) 2008-12-16
KR20040086301A (ko) 2004-10-08
WO2003063844A2 (en) 2003-08-07
JP4398731B2 (ja) 2010-01-13
PL370264A1 (en) 2005-05-16
NZ534137A (en) 2007-03-30
IL162983A (en) 2010-06-16
JP2005526022A (ja) 2005-09-02
ZA200405323B (en) 2005-08-31
RU2322238C2 (ru) 2008-04-20
MXPA04007309A (es) 2005-09-12
EP1471916A2 (en) 2004-11-03
US20060264443A1 (en) 2006-11-23
DE60321888D1 (enExample) 2008-08-14
DK1471916T3 (da) 2008-10-20
CA2473158A1 (en) 2003-08-07
RU2004126447A (ru) 2005-07-10
SI1471916T1 (sl) 2008-12-31
GB0201882D0 (en) 2002-03-13
BR0307286A (pt) 2004-12-28
CA2473158C (en) 2013-06-11
KR101030416B1 (ko) 2011-04-20

Similar Documents

Publication Publication Date Title
Keystone et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
US9345702B2 (en) Methods of treatment using selective Bcl-2 inhibitors
KR100824491B1 (ko) 면역염증 질환의 치료를 위한 조합
US20090131382A1 (en) Treatment of rheumatoid arthritis using imatinib
WO2011111143A1 (ja) 関節リウマチ薬
US20220370467A1 (en) Using of a ppar-delta agonist in the treatment of kidney disease
WO2008087437A1 (en) Treatment of corticoid-resistant asthma or copd with p38 map kinase inhibit (eg. sb2035809)
CN1229113C (zh) 用于治疗自身免疫性疾病的药物组合物
JP2005526022A5 (ja) 関節リウマチの処置
JP2022523018A5 (enExample)
JP2025513474A (ja) 好中球性皮膚疾患の治療
AU2007201056B2 (en) Treatment of rheumatoid arthritis using imatinib
WO2021108338A1 (en) A combination of a btk inhibitor and abatacept for the treatment of rheumatoid arthritis
HK1072192B (en) Treatment of rheumatoid arthritis using imatinib
AU2003206783A1 (en) Treatment of rheumatoid arthritis using imatinie
C Nossent, Gunstein Bakland, Hanne Karen Aslaksen, Gunn Olsen, Bjørn Yngvar Nordvåg Efficacy of methylprednisolone pulse therapy versus infliximab in the treatment of severe flares of chronic polyarthritis
EP3784243B1 (en) Methotrexate for use as a medicament
HK40113661A (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
WO2025134072A1 (en) Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
TW202545518A (zh) 三稠環化合物在製備預防和/或治療炎性疾病藥物中的應用
Suresh et al. Efficacy of etanercept compared to combination of etanercept and methotrexate in patients with rheumatoid arthritis with a sparse response to methotrexate
CA2488066A1 (en) Treatment of spondylarthropathies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination